SCHEMBL731594

SCHEMBL731594

CC1C[C](F)C(F)(C(C)C)C(F)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11293034 0.63
SCHEMBL1891341 0.60
SCHEMBL25897323 0.57
SCHEMBL25897324 0.57
SCHEMBL4337864 0.54
SCHEMBL17675856 0.54
SCHEMBL4546674 0.54
SCHEMBL24868375 0.52
SCHEMBL17490369 0.51 APLNR (0.35)
SCHEMBL19386283 0.49

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051329-B2 Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors MERCK SHARP & DOHME CORP. (US) 2015-06-09 US claimed
EP-2729468-A2 TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-05-14 EP claimed
US-20140113920-A1 TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-04-24 US claimed
WO-2013006526-A2 TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-10 WO claimed
US-8136974-B2 Metal coordination compound and light-emitting material containing the same NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2012-03-20 US claimed
US-7622578-B2 Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate WYETH (US) 2009-11-24 US claimed
US-7410995-B1 N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders GPI NIL HOLDINGS INC. (US) 2008-08-12 US claimed
US-7018994-B2 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17α-ALKYL-17β-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS SCHERING AG (DE) 2006-03-28 US claimed
US-6770599-B2 Tetrazole derivatives BAYER CROPSCIENCE KK (JP) 2004-08-03 US claimed
US-6677348-B2 INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2004-01-13 US claimed
US-6238440-B1 OXIDATION-DYEING HAIR L'OREAL S.A. (FR) 2001-05-29 US claimed
US-5753661-A TREATMENT OF NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS H. LUNDBECK A/S (DK) 1998-05-19 US claimed
US-4721729-A Novel carbacyclins, process for the preparation thereof, and their use as medicinal agents SCHERING AKTIENGESELLSCHAFT (DE) 1988-01-26 US claimed
US-4657898-A CARDIOVACULAR AND PSYCHOLOGICAL DISORDERS, ANALGESICS, OR SEDATIVES WARNER-LAMBERT COMPANY (US) 1987-04-14 US claimed
US-20050182047-A1 Treatment of demyelinating disorders EISAI CO., LTD. (JP) 2005-08-18 US disclosed
US-20050130979-A1 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders EISAI CO., LTD. (JP) 2005-06-16 US disclosed
US-20040204347-A1 Treatment of demyelinating disorders EISAI CO., LTD. (JP) 2004-10-14 US disclosed
EP-1100504-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS Eisai Co., Ltd. (JP) 2001-05-23 EP disclosed
WO-2000001376-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS EISAI CO., LTD (JP) 2000-01-13 WO disclosed